Categories AlphaGraphs, Consumer, Earnings
Earnings Infographic: A snapshot of Nike’s Q3 2024 results
Nike, Inc. (NYSE: NKE) has reported a decrease in earnings for the third quarter of 2024, when the sneaker giant’s revenues remained broadly unchanged.
Third-quarter net income was $1.17 billion or $0.77 per share, compared to $1.24 billion or $0.79 per share in the corresponding period of fiscal 2023. The bottom line was negatively impacted by flat sales.
February-quarter revenues remained unchanged year-over-year at $12.43 billion. NIKE Direct revenues were $5.4 billion, slightly higher on a reported and currency-neutral basis.
“Our teams are focused on what matters most to return to strong growth. We are taking action to build a faster, more efficient NIKE and maximize the impact of our new innovation cycle,” said Matthew Friend, Nike’s chief financial officer.
Prior Performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
